A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 12 weeks oral treatment with ACH126, 433 (b-L-Fd4C) [elvucitabine] in adults with lamivudine-resistant chronic hepatitis B
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2009
At a glance
- Drugs Elvucitabine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Oct 2005 New trial record.